UNSPSC 51282935: Oxolinic acid

This classification denotes a quinolone antibiotic with the molecular formula C13H11NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0A22B22FT, chemically known as 1,3-dioxolo(4,5-g)quinoline-7-carboxylic acid, 5-ethyl-5,8-dihydro-8-oxo- but generally known as oxolinic acid, which bears US NIH Compound Identifier 4628. European Medicines Agency schedules Oxolinic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09548MIG. The term OXOLINIC ACID is an International Non-Proprietary Name.

UNSPSC 51282935 Oxolinic acid, a Commodity code, shows a mismatch between its nominal scope and recent state and local procurement activity. The code's product definition does not align with the opportunities currently tagged under it; state and local governments are soliciting naloxone, pharmacy benefit program capabilities, medical and first aid supplies for emergency response, and generic pharmaceuticals and OTC products—none of which are oxolinic acid or directly related to its chemical class. The issuing bodies span multiple jurisdictions: a county health department (Seminole County, Florida), a state health agency (Texas Health and Human Services Commission), a city fire department procurement (City of Tampa), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). The scope of actual buying includes naloxone distribution for community health, direct-to-manufacturer pharmacy contracts, emergency medical supplies for fire rescue operations, and generic pharmaceutical sourcing through authorized wholesalers—work that falls under medical product supply, pharmaceutical procurement, and emergency response equipment rather than the narrow chemical compound the code nominally describes.

Recent activity concentrates in Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the Texas HHS Commission's Request for Information on direct-to-manufacturer prescription programs (due April 3, 2026), the City of Tampa's IFB for 169 line items of medical and first aid supplies for its Fire Department Rescue Division with an estimated contract value of $700,000 and a sheltered small local business enterprise set-aside (due March 13, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (due March 26, 2026). The code shows limited utility for vendors pursuing state and local opportunities in its stated scope; the tagging appears to reflect a procurement system classification error rather than genuine demand for oxolinic acid.